-DOCSTART- -X- O
The -X- _ O
peer-reviewed -X- _ O
marine -X- _ O
pharmacology -X- _ O
literature -X- _ O
in -X- _ O
2007–8 -X- _ O
is -X- _ O
covered -X- _ O
in -X- _ O
this -X- _ O
review -X- _ O
, -X- _ O
which -X- _ O
follows -X- _ O
a -X- _ O
similar -X- _ O
format -X- _ O
to -X- _ O
the -X- _ O
previous -X- _ O
1998–2006 -X- _ O
reviews -X- _ O
of -X- _ O
this -X- _ O
series. -X- _ O
The -X- _ O
preclinical -X- _ O
pharmacology -X- _ O
of -X- _ O
structurally -X- _ O
characterized -X- _ O
marine -X- _ B-Intervention
compounds -X- _ I-Intervention
isolated -X- _ O
from -X- _ O
marine -X- _ O
animals -X- _ O
, -X- _ O
algae -X- _ O
, -X- _ O
fungi -X- _ O
and -X- _ O
bacteria -X- _ O
is -X- _ O
discussed -X- _ O
in -X- _ O
a -X- _ O
comprehensive -X- _ O
manner. -X- _ O
Antibacterial -X- _ B-Outcome
, -X- _ I-Outcome
anticoagulant -X- _ I-Outcome
, -X- _ I-Outcome
antifungal -X- _ I-Outcome
, -X- _ I-Outcome
antimalarial -X- _ I-Outcome
, -X- _ I-Outcome
antiprotozoal -X- _ I-Outcome
, -X- _ I-Outcome
antituberculosis -X- _ I-Outcome
and -X- _ I-Outcome
antiviral -X- _ I-Outcome
activities -X- _ I-Outcome
were -X- _ I-Outcome
reported -X- _ I-Outcome
for -X- _ I-Outcome
74 -X- _ I-Outcome
marine -X- _ I-Outcome
natural -X- _ I-Outcome
products. -X- _ I-Outcome
Additionally -X- _ I-Outcome
, -X- _ I-Outcome
59 -X- _ I-Outcome
marine -X- _ I-Outcome
compounds -X- _ I-Outcome
were -X- _ I-Outcome
reported -X- _ I-Outcome
to -X- _ I-Outcome
affect -X- _ I-Outcome
the -X- _ I-Outcome
cardiovascular -X- _ I-Outcome
, -X- _ I-Outcome
immune -X- _ I-Outcome
and -X- _ I-Outcome
nervous -X- _ I-Outcome
systems -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
to -X- _ I-Outcome
possess -X- _ I-Outcome
anti-inflammatory -X- _ I-Outcome
effects. -X- _ I-Outcome
Finally -X- _ O
, -X- _ O
65 -X- _ O
marine -X- _ O
metabolites -X- _ O
were -X- _ O
shown -X- _ O
to -X- _ O
bind -X- _ O
to -X- _ O
a -X- _ O
variety -X- _ O
of -X- _ O
receptors -X- _ O
and -X- _ O
miscellaneous -X- _ O
molecular -X- _ O
targets -X- _ O
, -X- _ O
and -X- _ O
thus -X- _ O
upon -X- _ O
further -X- _ O
completion -X- _ O
of -X- _ O
mechanism -X- _ O
of -X- _ O
action -X- _ O
studies -X- _ O
, -X- _ O
will -X- _ O
contribute -X- _ O
to -X- _ O
several -X- _ O
pharmacological -X- _ O
classes. -X- _ O
Marine -X- _ O
pharmacology -X- _ O
research -X- _ O
during -X- _ O
2007–8 -X- _ O
remained -X- _ O
a -X- _ O
global -X- _ O
enterprise -X- _ O
, -X- _ O
with -X- _ O
researchers -X- _ O
from -X- _ O
26 -X- _ O
countries -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
United -X- _ O
States -X- _ O
, -X- _ O
contributing -X- _ O
to -X- _ O
the -X- _ O
preclinical -X- _ O
pharmacology -X- _ O
of -X- _ O
197 -X- _ B-Intervention
marine -X- _ I-Intervention
compounds -X- _ I-Intervention
which -X- _ O
are -X- _ O
part -X- _ O
of -X- _ O
the -X- _ O
preclinical -X- _ O
marine -X- _ O
pharmaceuticals -X- _ O
pipeline. -X- _ O
Sustained -X- _ O
preclinical -X- _ O
research -X- _ O
with -X- _ O
marine -X- _ O
natural -X- _ O
products -X- _ O
demonstrating -X- _ O
novel -X- _ O
pharmacological -X- _ O
activities -X- _ O
, -X- _ O
will -X- _ O
probably -X- _ O
result -X- _ O
in -X- _ O
the -X- _ O
expansion -X- _ O
of -X- _ O
the -X- _ O
current -X- _ O
marine -X- _ O
pharmaceutical -X- _ O
clinical -X- _ O
pipeline -X- _ O
, -X- _ O
which -X- _ O
currently -X- _ O
consists -X- _ O
of -X- _ O
13 -X- _ O
marine -X- _ O
natural -X- _ O
products -X- _ O
, -X- _ O
analogs -X- _ O
or -X- _ O
derivatives -X- _ O
targeting -X- _ O
a -X- _ O
limited -X- _ O
number -X- _ O
of -X- _ O
disease -X- _ O
categories -X- _ O
. -X- _ O

